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Background: Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment
strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant
proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this
considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical
response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to
identify biomarkers capable of predicting complete response to nCRT.
Methods: We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT.
Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients
to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two
cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT.
Results: We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In
addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as
being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in
predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with
cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to
incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene,
whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments
and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients.
Conclusions: This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of
patients with cCR to nCRT that potentially could be spared from radical surgery.
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Treatment of locally advanced rectal cancer includes a
combination of surgery and radiotherapy with or with-
out chemotherapy (CRT and RT, respectively). In recent
years, preoperative delivery of RT or CRT has become
one of the preferred initial treatment options for the
management of rectal cancer due to improved local
disease control and significant tumor regression [1-3].
Tumor regression to neoadjuvant chemoradiation
(nCRT) varies substantially among patients, and ultim-
ately, complete pathological response (pCR) may develop
in up to 42% of them [4]. These patients with pCR are
associated with excellent oncological outcomes, particu-
larly in terms of local disease control. Considering that
radical surgery does not remove any residual cancer in
these patients, alternative treatment strategies to this
procedure have been considered in an effort to avoid
unnecessary postoperative morbidity and mortality. A
strategy of close observation without immediate sur-
gery, known as ? Watch and Wait ? , has been proposed
for highly selected patients with no clinically or radio-
logically detectable residual tumor (complete clinical re-
sponse ? cCR) [5]. This strategy requires an intensive
follow-up in which patients are submitted to frequent
clinical, endoscopic and radiological assessments after
completing nCRT [6].
However, clinical and radiological assessment of tumor
response remains a significant challenge due to their
subjectivity and inherent limitations of currently available
studies. In this setting, identification of molecular markers
capable of predicting complete response to nCRT would
not only allow accurate selection of patients that benefit
the most from nCRT but also identify ideal candidates to
alternative treatment strategies without immediate radical
surgery after achieving cCR.
miRNAs are small non-coding RNAs (18-25 nt) cap-
able of regulating mRNAs post-transcriptionally by
inducing their destabilization or translational repression
[7]. miRNAs play important regulatory roles in several
cellular processes such as cell proliferation, differenti-
ation, and apoptosis. Changes in their expression profile
have been reported for several types of cancer [8]. In fact,
miRNAs may contribute to the tumorigenic process
functioning as tumor suppressor genes or oncogenes
depending on the genes they regulate [9,10].
Importantly, different studies have also investigated
how miRNA profiling may be associated with treatment
response in different tumor types, motivating the search
for their role as predictive molecular markers in cancer
[11-13]. The goal of the present study was to compare
miRNA expression profile of treatment-naive tumor
biopsies derived from rectal cancer patients with complete
or incomplete response to nCRT in order to identify
specific miRNAs as predictive biomarkers.Methods
Patients and biological samples
Patients with biopsy-proven rectal adenocarcinoma,
cT2-4 N0-2 M0 located no more than 7 cm from the
anal verge measured by rigid proctoscopy were eligible
for the study. All patients were radiologically staged
using high-resolution pelvic MRI, abdominal and chest
CT scans and CEA levels. Patients with pregnancy or
under the age of 18 were excluded from the study.
Endoscopic biopsies were taken from primary tumors,
properly identified and snap frozen using liquid nitrogen
prior to storage at −80?C. Tumor fragments were veri-
fied for the presence of ≥80% viable cancer cells prior to
RNA extraction using standard hematoxilin-eosin stain-
ing. Specimens with <80% cancer cells were macro-
dissected to result in ≥80% of cancer cells.
This study was approved by the ethics committee from
Hospital Alem?o Oswaldo Cruz (Sao Paulo, Brazil -
reference number 19/08). Informed consent was obtained
from all study participants prior to sample collection.
Treatment and assessment of response
All patients underwent nCRT as described elsewhere [5].
Briefly, nCRT consisted of 50.4-54Gy of radiation and
concomitant 5FU-based chemotherapy. Patients were
clinically reassessed for tumor response at least 12 weeks
from nCRT completion using digital rectal examination,
rigid proctoscopy, pelvic MRI and CEA levels [6]. Patients
with evidence of residual disease (incomplete clinical
response) such as residual ulcers, irregularity, mass or
stenosis at clinical examination were referred to imme-
diate radical surgery. Likewise, patients with radiological
evidence of residual disease including the presence of
nodal metastases or residual primary cancer were also
referred to radical surgery. Patients with clinical, endo-
scopic or radiological evidence of cCR were recom-
mended no immediate radical surgery and were enrolled
in a strict follow-up program (Watch & Wait strategy) [5].
Groups for comparison
Based on chronological order, the first patients matching
our criteria were included in the training set (27 sam-
ples) and the samples collected later on were included in
the validation set (16 samples). Patients were grouped
according to response to nCRT based on clinical and
pathological findings. The complete responders group
included patients with clinical evidence of complete
response (cCR) sustained for at least 24 months of
follow-up and patients with complete pathological re-
sponse (pCR) who underwent radical surgery due to
inability to rule out residual disease. The incomplete
responders group included patients with significant re-
sidual disease detected after pathological examination
of the resected specimen, including ypT2-4 or ypN+
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TRG0-2 according to Dworak? s classification [14]. There-
fore, patients with incomplete but with ? near-complete?
response including ypT1N0 or ≤10% residual cancer cells
(TRG3) were excluded from the study. Differential miRNA
expression analyses were performed comparing the
complete to incomplete responders.
miRNA sequencing analysis
Total RNA was extracted with Trizol reagent (Invitrogen),
and RNA quality was evaluated on 2100 Bioanalyzer
(Agilent). All samples had RNA integrity number (RIN)
above 6. Total RNA (10 μg) was enriched for small
RNAs (up to 250 bp) using PureLink ? miRNA Isolation
Kit (Invitrogen). miRNA libraries were prepared using
SOLiD ? Total RNA-Seq Kit (Life Technologies), accord-
ing to the manufacturer ? s recommendations and were
sequenced on SOLiD4 (Life Technologies) in 35 bp
single read runs.
Sequencing data was analyzed using the CLC Genomics
Workbench 5.1 software (CLC Bio). Initially, sequencing
adapters were trimmed from sequencing reads. The
remaining sequences were mapped against the human
miRNA database, miRBase (www.mirbase.org, release
18) [15,16], allowing one mismatch. At last, known ma-
ture miRNAs were annotated according to miRBase and
the number of sequences for each miRNA was used for
differential expression analysis. Normalization was done by
dividing the number of sequences of a certain miRNA by
the total number of miRNA mapped sequences for a given
sample and multiplying by one million. This resulted in a
value corresponding to the number of sequences (counts)
per million (cpm) for each miRNA. After normalization,
low expressed miRNAs were filtered from further analysis
to increase detection power of the statistic tests. Only miR-
NAs with a minimum of 20 cpm in at least seven samples
were kept in the analyses (Additional file 1: Table S1).
Differential expression between the two groups of
patients was performed with EdgeR (version 2.6.7) [17]
available on Bioconductor 2.10 [18]. P-values were
adjusted for multiple testing using the Benjamini and
Hochberg method to control the false discovery rate
(FDR) [19]. Only miRNAs with FDR under 0.05 were
considered as differently expressed.
Clustering and response prediction analysis
Hierarchical clustering and bootstrap statistical analysis
were performed using the functions ? heatmap ? and
? pvclust ? available in the R statistical software (version
3.0.1). These analyzes were based on Euclidean distance
and average linkage clustering using cpm normalized
data. Principal Component Analysis (PCA) was per-
formed using the Matlab language function ? princomp ?
(version R2009b). PCA was carried out by eigenvaluedecomposition of the covariance matrix after mean
centering the data matrix for each attribute. The first
principal component (i.e., the direction along which
miRNAs expression show the largest variance) and the
second principal component (i.e., the next best direction
uncorrelated with first one) were retrieved and plotted
to illustrate similarities between samples.
Receiver operating characteristic (ROC) curve for each
miRNA was generated using cpm values obtained from
RNA-Seq data, using GraphPad Prism software (version
4.03). To determine accuracy to predict nCRT, the area
under the ROC curve (AUC) was calculated. The cutoff
expression values (cpm) were defined in order to maximize
the number of correctly classified samples. Finally,
sensitivity and specificity based on this cutoff were
calculated.
miR-21-5p putative target genes
We initially used TargetScan software (www.targetscan.
org) to search for predicted miR-21-5p targets [20]. We
considered only conserved sites in conserved target genes.
Using whole transcriptome sequencing data from 19 of
the primary rectal tumors used in this study (unpublished
data), we searched for the expression of predicted targets
that were inversely correlated (Pearson correlation) to
miR-21-5p expression using GraphPad Prism software
(version 4.03).
Further exploring whole transcriptome data, SATB1 gene
expression was compared between incomplete responders
(n = 13) and complete responders (n = 6). Mann? Whitney
test was performed using GraphPad Prism software
(version 4.03).
Validation of miR-21-5p and SATB1 expression by qPCR
miR-21-5p and SATB1 gene expression was evaluated
through qPCR in 10 and 11 samples, respectively (the
samples that were used for validation of SATB1 were the
same as the samples for miR-21-5p plus another sample
from an incomplete responder that still had RNA avail-
able). For miR-21-5p, the QIAGEN miScript PCR system
was used. cDNA was generated with miScript II RT kit
(QIAGEN) and 3 ng were used as template in each
qPCR reaction. miR-21-5p miScript primer assay and
miScript SYBR Green PCR kit were also used. Reactions
were performed in triplicates using 7900HT Fast System
(Applied Biosystems). Based on our miRNA-Seq data, we
chose miR140-5p and miR-224-5p to be used for nor-
malization of qPCR experiments since they were most
stably expressed miRNAs among our samples [21,22].
SATB1 gene expression was evaluated with GoTaq? qPCR
Master Mix (Promega) using the following primers:
SATB1Fw: GGTACAAACATTTCAAGAAGAC and SAT-
B1Rev: CATGATTGGCGCCTTGCT. PUM1 and HMBS
genes were used for normalization (PUM1Fw: TGTACTT
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CGGAAGAT; HMBSFw: GGCAATGCGGCTGCAA HM
BSRev: GGGTACCCACGCGAATCAC).
Relative expression was calculated based on ΔΔCT
method using a colorectal cancer cell line (HCT116) as
reference sample [23]. Mann ? Whitney test was per-
formed using GraphPad Prism software (version 4.03).
Clonogenic assays
Colorectal tumor cell lines, HCT116 and SW480, were
obtained from American Type Culture Collection (ATCC),
and cultured following their recommendations.
Cells were plated at a low density (500 cells/well) in 4
wells plates (1.9 cm2 well area) and transfections were
carried out with Lipofectamine? RNAiMAX Transfection
Reagent (Invitrogen). HCT116 were transiently transfected
with 30 nM mirVana? miRNA Inhibitors (hsa-miR-21-5p
or inhibitor control) and SW480 were transfected with 10
nM mirVana? miRNA Mimics (hsa-miR-21-5p or mimic
control) (Life Technologies). 24 h after transfection, cells
were treated with 5 μM 5-fluorouracil (5-FU, Libbs) and ir-
radiated with 1 Gy dose for HCT116 and 2Gy for SW480
using GammaCell 3000 equipment (Elan). After 12 days,
colony formation was quantified. Cells were fixed with for-
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ypNx - 0colony quantification, the dye from stained cells was solu-
bilised with 10% acetic acid and absorbance was measured
at 595 nm using Infinite 200 PRO (Tecan Group Ltd).
Two independent experiments were performed in quadru-
plicates for each cell line.
Results
Training and validation sets of patients
Clinical and demographics features of all 43 patients
included in this study are summarized in Table 1. Overall,
27 patients were analyzed in the training set, including 7
complete responders and 20 incomplete responders. In
addition, 16 patients were analyzed as a validation set,
being 7 complete responders, 5 incomplete responders
and 4 patients that initially presented cCR but developed
early local recurrence (within the first 16 months of
follow-up after nCRT).
miRNA differential expression to predict nCRT
Primary tumor biopsies were collected before nCRT and
used for small RNA sequencing. On average, 37 million
sequences were generated for each sample. After map-
ping and annotation, 711 mature miRNAs were detected
per sample. The number of sequences for each specific
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detection power of statistic tests. Finally, we performed
differential expression analysis using, on average, 330 ma-
ture miRNAs for each sample (Additional file 1: Table S1).
The first approach to identify molecular markers
capable of predicting tumor response to nCRT was to
perform differential miRNA expression analysis using the
27 samples from the training set. Comparison between
complete and incomplete responders showed 36 dif-
ferently expressed miRNAs (p < 0.05). In order to apply
a more stringent control over false positives, p-values
were adjusted for multiple testing, which controls false
discovery rate (FDR) [19]. Thus, 4 miRNAs had a FDR
< 0.05 and were considered as reliable differentially
expressed when comparing complete to incomplete
responders (Table 2). Three miRNAs were overexpressed
in complete responders (miR-21-5p, miR-1246, and miR-
1290-3p) and one, miR-205-5p, was overexpressed in
incomplete responders.
After determining differentially expressed miRNAs, we
evaluated their efficiency in discriminating complete
responders from incomplete responders ? patients. First,
we performed hierarchical clustering analysis which
resulted in two major groups, one containing only incom-
plete responders and the other one with all complete
responders plus 3 incomplete responders (Figure 1A). Sec-
ond, the expression level (given in count per million, cpm)
of the 4 differentially expressed miRNAs was used to
perform Principle Component Analysis (PCA). This
analysis revealed good separation between complete
and incomplete responders (Figure 1B). Consistent with
the hierarchical clustering analysis, the same 3 incom-
plete responders showed greater similarity with patients
from the complete responders group.
miRNAs as potential predictive markers
We have also investigated the potential of each of the 4
differently expressed miRNAs to be individually used as
a predictive biomarker. In order to estimate the effi-
ciency on correctly classifying patients according to
treatment response, we calculated the area under the
ROC curve (AUC) for each miRNA. We found an AUC
of 0.94, 0.74, 0.70, and 0.63 for miR-21-5p, miR-1246,









miRNAs mean expression is shown for each response group to nCRT and fold chan
significance can be verified by P-values and false discovery rate (FDR).Also, the expression cutoff point was determined for
each miRNA to maximize sensitivity and specificity.
Considering the normalized expression values (in cpm)
obtained by RNA-Seq, the established cutoff for each
miRNA resulted in a sensitivity and specificity of 100%
and 85% for miR-21-5p, 86% and 65% for miR-1246,
71% and 75% for miR-1290-3p, and 86% and 55% for
miR-205-5p, respectively (Figure 2). These results sug-
gested miR-21-5p as the best putative predictive marker.
Validation of miRNA differential expression in
independent samples
In order to verify whether the differential expression of
these miRNAs was not limited to the training set of
samples, we have also analyzed a validation set of sam-
ples, including 7 complete responders and 5 incomplete
responders. miRNAs libraries from these primary tu-
mors were sequenced and global differential expression
analysis between complete and incomplete responders
was performed. Thus, we found miR-21-5p as a com-
mon differently expressed miRNA (p-value < 0.01). The
other 3 miRNAs did not show differential expression in
the validation set and therefore, were not used in the
following analyses.
To further validate miR-21-5p as a predictive marker
for nCRT, we also analyzed its expression in samples
from patients that initially presented cCR to nCRT and
were spared from immediate surgery but during follow
up visits, presented early local recurrence requiring
salvage resection (named here as early recurrence group).
These patients most definitely had clinically undetectable
residual disease after nCRT. Noteworthy, miR-21-5p
expression pattern in these patients was very similar to
incomplete responders (Figure 3). More importantly,
miR-21-5p expression in these two groups of patients
(incomplete responders and early recurrence group)
was significantly lower than the complete responders
group (p-value <0.01). These results indicated that
although physicians could not distinguish between pa-
tients who presented ? bona fide ? complete response and
patients who initially presented complete clinical re-
sponse but faced early local recurrence, they have
tumors with important molecular differences, including
miR-21-5p expression.sponders
ion (cpm)





ge of complete responders relative to incomplete responders. Statistical
Figure 1 Patients? clustering based on the expression of 4 differently expressed miRNAs. A) Hierarchical clustering heatmap for incomplete
(I) and complete responders (C). B) PCA was conducted for 27 samples and 4 variables (differently expressed miRNAs). Blue dots: complete responders;
red dots: incomplete responders.
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of miR-21-5p expression using the cutoff established on
the ROC curve for the training set (70,000 cpm) and all
the samples included in the study (from training and valid-
ation set). For this estimation, we considered the early
recurrence group as incomplete responders. Thus, miR-
21-5p expression presented 78.5% (11/14) sensitivity and
86% (25/29) specificity to identify patients with complete
response to nCRT. Similarly, miR-21-5p expression also
showed good positive (73%, 11/15) and negative predictive
values (89%, 25/28).
Finally, we have also validated the miR-21-5p differential
expression by qPCR, a more easily and cheaper imple-
mented method compared to deep-sequencing. Since our
samples were all pre-treatment rectal tumor biopsies, theyyielded a limited amount of RNA usually completely
used for miRNA library construction. Therefore, for
qPCR validation, we only tested 10 samples that still
had RNA available (3 complete responders and 7 in-
complete responders). The higher miR-21-5p expres-
sion in complete responders was once again validated
(Additional file 2: Figure S1). However, possibly due to
the small number of samples tested, this difference was
not statistically significant (p-value = 0.067).
We have also investigated whether miR-21-5p expres-
sion was associated with clinical and pathological pa-
rameters. In order to do that, we categorized samples
into two groups: high miR-21-5p expression (expression
above the established cutoff, 70,000 cpm) and low miR-
21-5p expression. No statistically significant association
Figure 2 Accuracy to predict nCRT based on the expression of differently expressed miRNAs. ROC curves were built based on miRNA
expression determined by RNA-Seq. Area under the curve (AUC), sensitivity (Sens) and specificity (Spec) were calculated for each miRNA.
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parameters analyzed, such as age, gender, tumor size,
tumor distance from anal verge, and initial T and N
staging (Additional file 3: Table S2).
Potential role of miR-21-5p on treatment response
In order to investigate whether miR-21-5p expression is
directly involved in treatment response, we analyzed the
expression pattern of its putative target genes using
whole transcriptome RNA-Seq data from 19 samples
of the training set patients (6 complete responders and
13 incomplete responders ? unpublished data). Using
TargetScan software [20], we found 307 predicted miR-
21-5p targets genes with high prediction score. Among
them, we were able to detect the expression (measured
in reads per kilobase of transcript per million reads
mapped, RPKM) for 249 genes in the 19 patients. Con-
sidering the negative regulation of miRNAs over their
target genes ? expression, we searched for predicted
targets for which the expression pattern was inversely
correlated to miR-21-5p expression. Using this approach,we only found a significant negative correlation (r = −0.5
and p-value = 0.03) for SATB1 gene (Figure 4A and
Additional file 4: Table S3). This is a global gene regu-
lator that has been reported to confer malignant behavior
and multidrug resistance (MDR), as well as being associ-
ated with poor prognosis in several cancer types, including
rectal cancer [24-26]. Even though other authors have
shown that miR-21-5p can regulate the expression of
other target genes such as PTEN, MSH2, Cdc25A, SPRY2
and PDCD4, and therefore be associated with worse re-
sponse to therapy in other tumor types, we did not
observe a significant inverse correlation between the ex-
pression of these target genes and of miR-21-5p in our
samples (Additional file 3: Table S4) [27-31].
It has already been shown that miR-21-5p can negatively
regulate SATB1 expression [32,33]. Indeed, we have con-
firmed such regulation in vitro by transiently manipulating
miR-21-5p expression in 2 different colorectal cancer cell
lines. HCT116 and SW480 cells were chosen because they
differ significantly on miR-21-5p expression levels: 5-fold
higher in HCT116 cells (Figure 5A). Thus, we have
Figure 3 miR-21-5p expression in all samples included in the study. Patients were divided in 3 groups according to nCRT response: patients
with initial cCR followed by early local recurrence (n = 4), incomplete responders (n = 25), and complete responders (n = 14). miR-21-5p expression
is given as normalized values (cpm) from RNA-Seq data. Statistical analysis was performed with EdgeR (*FDR < 0.05).
Lopes-Ramos et al. BMC Medical Genomics 2014, 7:68 Page 8 of 14
http://www.biomedcentral.com/1755-8794/7/68transfected SW480 cells with miR-21-5p mimic and
observed by qPCR a reduction on SATB1 mRNA
expression (Figure 5B). Accordingly, we have knocked-
down miR-21-5p expression in HCT116 cancer cells and
observed an increased expression of SATB1 (Figure 5C).
These results confirmed the negative regulation of
miR-21-5p on SATB1 expression and corroborated the
negative correlation of their expression observed in
our patients ? samples.Figure 4 Expression analysis of SATB1 gene. A) Correlation between SA
primary rectal tumors. r: Pearson correlation factor. B) SATB1 expression accor
responders (n = 6). SATB1 expression is given as normalized values (rpkm). MaFurther exploring the whole transcriptome data from
these 19 patients, we found a significantly higher SATB1
expression in incomplete responders compared to complete
responders, according to our hypothesis (p-value = 0.01)
(Figure 4B). In addition, we have also evaluated SATB1
expression by qPCR in 11 primary tumors (3 complete
and 8 incomplete responders). A higher SATB1 expres-
sion in incomplete responders was once again observed.
However, similar to what we observed for miR-21-5p, thisTB1 and miR-21-5p expression, measured by RNA-Seq, in the same
ding to nCRT response: incomplete responders (n = 13), and complete
nn? Whitney test performed.
Figure 5 Manipulation of miR-21-5p expression negatively correlates with SATB1 mRNA expression. A) Evaluation of miR-21-5p expression by
qPCR shows that HCT116 and SW480 cells express different levels. B) miR-21-5p and SATB1 mRNA expression were evaluated by qRT-PCR 24 hours
after transient transfection of SW480 cell line with miR-21-5p mimic or mimic control; C) miR-21-5p and SATB1 mRNA expression was evaluated
24 hours after transient transfection of HCT116 cell line with miR-21-5p inhibitor or inhibitor control. Bars represent mean expression relative to
control and normalized by RNU6b (for miR-21-5p) and HMBS (for SATB1). Error bars represent standard deviation for quadruplicates in 2 independent
experiments. *P < 0.005 for Student? s t-test.
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(Additional file 2: Figure S2). These results suggest SATB1
as a potential candidate for functional studies, which could
elucidate the possible direct involvement of miR-21-5p
in response to nCRT in rectal cancer patients.
miR-21-5p and SATB1 expression in colorectal cancer cells
is directly involved with treatment response
Further exploring the involvement of miR-21-5p on
response to nCRT in rectal cancer patients we have
challenged HCT116 and SW480 colorectal cancer cell
lines to a similar treatment in vitro. In order to prop-
erly evaluate the role of miR-21-5p, we have transiently
manipulated its expression in both of them and per-
formed clonogenic assays to verify whether there were
changes on their sensitivity to the chemoradiationtreatment. Experiments were performed with cells
cultured under control conditions as well as submitted
to one dose of radiation combined with 5-FU treatment
(see details in Methods).
Firstly, SW480 cells were transiently transfected with
miR-21-5p mimic and mimic control, and submitted to
the clonogenic assay. As expected, miR-21-5p increased
expression resulted in decreased SATB1 expression and
also turned SW480 cells more sensitive to chemoradia-
tion treatment (Figure 6A). Similarly, HCT116 cells,
which express higher levels of miR-21-5p, were transi-
ently transfected with mir-21-5p inhibitor and inhibitor
control, and submitted to the clonogenic assay. Inhib-
ition of miR-21-5p expression resulted in an increased
SATB1 expression and decreased sensitivity to chemora-
diation treatment (Figura 6B). According to our findings
Figure 6 Manipulation of miR-21-5p expression alters response to chemoradiation in vitro. A) Quantification of colony formation assays for
SW480 cell line transfected with miR-21-5p mimic or mimic control. B) Quantification of colony formation assays for HCT116 cell line transfected with
miR-21-5p inhibitor or inhibitor control. Cells were grown under control conditions or submitted to CRT treatment, which consisted of 5 μM 5-FU and
a single dose of 2Gy (A) or 1Gy (B) radiation. Graphs show relative absorbance of colonies stained with crystal violet, normalized to untreated controls.
All values are presented as means ? s.d. relative to mimic or inhibitor controls from two independent experiments with quadruplicates. *P < 0.005 for
Student? s t-test.
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of SATB1 expression, miR-21-5p is directly involved on
response to chemoradiotherapy.
Discussion
Standard treatment of locally advanced rectal cancer
may include nCRT followed by radical surgery in most
patients. However, the observation of pCR in up to 42%of patients undergoing nCRT has challenged the role of
radical surgery in this setting and alternative treatment
strategies for these patients have been suggested [4,5,34].
Identification of these patients by clinical and imaging
assessments may be very difficult and remains restricted
to specific dedicated centers. Therefore, most of these
patients still undergo potentially unnecessary radical
surgery including total mesorectal excision. Molecular
Lopes-Ramos et al. BMC Medical Genomics 2014, 7:68 Page 11 of 14
http://www.biomedcentral.com/1755-8794/7/68markers capable of accurately predicting tumor response
to nCRT would be of great clinical significance since
these patients could be spared from radical surgery and
from morbidities associated with this procedure.
Previous studies searching for predictive molecular
markers in rectal cancer patients have used microarray
and qPCR to evaluate mRNA or miRNA profiling [35-42].
However, patients? response classification varied consider-
ably among these studies. The ? Responders? group fre-
quently included complete pathological responders and
partial responders (based on T-level downstaging or
tumor regression grades). In addition, although it has been
shown that pCR rates may considerably increase up to
12 weeks after nCRT, most of these studies have assessed
tumor response at considerably short intervals from nCRT
(most frequently after 6 weeks) [35,37,38,43]. Thus, com-
parison between studies may be quite difficult and rather
inconclusive. Regarding miRNA profiling, three recent
studies have identified signatures with good accuracy to
predict nCRT response [40-42]. However, none of them
validated their signatures in an independent group of pa-
tients. Importantly, comparing the molecular signatures,
there is no overlapping miRNA among them, suggesting
that these signatures might be characteristic of the sam-
ples used in each study.
To the best of our knowledge, this is the first study to
perform global miRNA sequencing followed by differen-
tial expression analysis of primary rectal tumor samples,
and to use, as complete response group, samples from
patients with pCR as well as with sustained cCR to
nCRT. In addition, the exclusion of patients with ? near-
complete ? responses rather than including them in
complete or incomplete responder groups allowed us to
compare only patients/tumors with significant clinical
discrepancies in their outcomes (response to nCRT),
favoring the identification of molecular differences. Using
this approach, we identified 4 differently expressed miR-
NAs between complete and incomplete responders in the
training set. Based on their expression and by performing
two different analyses (hierarchical clustering and PCA),
samples could be clustered into two distinct groups. Im-
portantly, in all of them, all 7 complete responders were
clustered together. The predictive power of each miRNA
was also estimated through ROC curves and miR-21-5p
showed the best accuracy (AUC= 0.94).
Due to clinical and molecular heterogeneity of tumor
samples, we expect that predictive markers found in one
group of samples might not be valid for a different group of
samples. Thus, miRNA differential expression was further
evaluated in additional samples. Among the 4 miRNAs,
miR-21-5p maintained a significant difference in expression
levels, being overexpressed in patients with complete
response to nCRT, and showing the potential of this
miRNA to be used as a predictive marker. Interestingly,in all patients with initial cCR followed by early local re-
currence, miR-21-5p showed an incomplete response
expression pattern. Thus, if miR-21-5p expression was
used to help physicians to decide whether to operate these
patients or not, they would have been correctly submitted
to surgery immediately after the resting period post-nCRT.
When used as a predictive marker on all samples in-
cluded in the study, miR-21-5p expression showed high
sensitivity (78.5%) and specificity (86%) on the identifica-
tion of complete responders. Among complete responders,
it is important to note that miR-21-5p expression was not
significantly different between pCR and cCR. Importantly,
considering only pCR patients, 4 out of 5 (80%) were
correctly predicted based on miR-21-5p expression.
These patients were submitted to surgery due to inabil-
ity to rule out residual disease by clinical and radio-
logical exams, suggesting again that a high percentage
of patients could benefit from such biomarker and be
spared from radical surgery. Although we have studied
a limited number of samples, this is the first study that
has used a validation set of samples to confirm the
differential expression observed in a training set. Thus,
miR-21-5p emerges as a promising predictive marker to
nCRT that still needs to be further validated in a larger
cohort.
miR-21-5p is overexpressed in different tumor types,
including colorectal cancer (CRC), possibly acting as an
oncogenic miRNA with important roles in cell prolifera-
tion, apoptosis and invasion [44-46]. Therefore, miR-21-
5p has been considered a promising diagnostic/prognostic
biomarker [47-49]. However, the literature is controversial
regarding miR-21-5p expression and treatment response.
Although several in vitro studies using CRC cell lines have
shown that overexpression of miR-21-5p induces resist-
ance to chemotherapy [30,31,50], few studies evaluated
miR-21-5p expression in CRC primary tumors and in the
context of radiotherapy. In one of these studies, patients
treated with adjuvant chemotherapy, high miR-21-5p
expression predicted worse overall survival, suggesting an
association between high miR-21-5p expression and poor
therapeutic outcome [51]. However, comparison between
these results and ours is not straightforward, since they
investigated miR-21-5p expression in the context of colon
adenocarcinoma, adjuvant chemotherapy and long-term
survival outcomes. All of these discrepancies lead to inher-
ent limitations in comparisons between studies and pos-
sibly yielding controversial findings.
In one of the few studies with rectal cancer patients sub-
mitted to nCRT, miR-21 expression was evaluated in
macrodissected tumor tissue before and after treatment,
and in normal rectal tissue from resection specimen [52].
There was no significant difference on miR-21 expression
level between pre and post-treatment tumor samples as
well as between post-treatment tumor and normal tissues.
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identification of their target genes. Considering the nega-
tive regulation imposed by miRNAs it can be assumed
that they perform an opposite role of their targets. Search-
ing for the expression of miR-21-5p targets in our sam-
ples, we found an interesting negative correlation for
SATB1 gene and miR-21-5p expression. As expected,
when we compared SATB1 expression among complete
and incomplete responders, a significantly higher expres-
sion was observed in incomplete responders. SATB1 is a
chromatin modifier and it has also been shown to be a
MDR gene in several cancer types [25,53,54].
As mentioned, although other authors have shown
that miR-21-5p can regulate the expression of other
target genes such as PTEN and MSH2, and therefore be
associated with worse response to therapy, we did not
observe an inverse correlation between the expression of
any these target genes and of miR-21-5p in our samples.
Therefore, as miRNAs ? function can be tissue specific,
we hypothesize that, in the context of rectal cancer sam-
ples, miR-21-5p might not be involved on the regulation
of these target genes.
Finally, we have also performed functional experi-
ments with two different cancer cell lines. We not only
confirmed the regulation of SATB1 expression by miR-
21-5p but more importantly, we have confirmed that
miR-21-5p and SATB1 play a direct role in response to
in vitro chemoradiation.
Conclusions
We have identified miR-21-5p as a promising predictive
marker for response to nCRT in rectal cancer patients.
Patients with cCR based on very stringent criteria and
high levels of miR-21-5p expression may be ideal candi-
dates for alternative treatment strategies to radical surgery
including a watch and wait approach. Further validation of
these findings in larger cohorts may lead to the inclusion
of this miRNA-based test in standard workup of patients
prior to nCRT and help in clinical decision-making for
patients with apparent cCR.
Additional files
Additional file 1: Table S1. Expression of miRNAs used for differential
expression analyses among complete and incomplete responders.
Samples from 1 to 14 represent complete responders patients, 15 to 39
represent incomplete responders patients, and 40 to 43 represent
patients with early local recurrence. Normalized expression values are
given in count per million (cpm).
Additional file 2: Figure S1. Evaluation of miR-21-5p by qPCR on
primary tumor samples. Samples still available included 7 incomplete and
3 complete responders to nCRT. A colorectal cancer cell line (HCT116)
was used as reference sample and the relative expression was calculated
based on ΔΔCT method using miR-140-5p and miR-224-5p expression for
normalization. Mann ? Whitney test performed. Figure S2. Evaluation of
SATB1 gene expression by qPCR on primary tumor samples. Samplesfrom 3 complete and 8 incomplete responders were used for SATB1
validation. A colorectal cancer cell line (HCT116) was used as reference
sample and the relative expression was calculated based on ΔΔCT
method using PUM1 and HMBS gene expression for normalization.
Mann ? Whitney test performed.
Additional file 3: Tables S2. Patients ? clinical characteristics distribution
according to miR-21-5p expression level (70,000 cpm cutoff established
based on the training group). Table S4. Expression of miR-21-5p and 5
of its published target genes in rectal cancer samples. Pearson correlation
was evaluated and only SATB1 gene presented a significant inversed
correlation (r = −0.5, p = 0.03).
Additional file 4: Table S3. Pearson correlation between the expression
of miR-21-5p and all putative target genes in rectal cancer samples.
Only SATB1 gene presented a significant inversed correlation (r = −0.5,
p = 0.03).
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